Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis, a third indication for the drug candidate. The Company will collaborate with the Cleveland Clinic through a new consulting agreement. “Synaptogenix is excited to work with this internationally recognized team of…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er FRJÁLS.
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- , a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis, a third indication for the drug candidate.
- The Company will collaborate with the Cleveland Clinic through a new consulting agreement.
- “Synaptogenix is excited to work with this internationally recognized team of….
